Omeros maintains a highly leveraged capital structure with $310.6 million in total debt and a persistent negative equity position that reached $63.3 million in 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|
| Total Current Assets | 180.35M | 215.67M | 134.12M | 217.9M | 443.24M | 247.96M | 151.28M | 103.75M | 89.87M | 108.37M | 60.26M | 37.15M | 9.16M | 14.82M | 24.7M | 25.95M | 43.75M | 60.66M | 20.48M | 24.46M |
| Cash & Short-Term Investments | 135.32M | 171.8M | 90.13M | 171.85M | 194.92M | 157.27M | 134.95M | 60.79M | 60.5M | 83.75M | 45.33M | 28.26M | 6.89M | 14.1M | 22.35M | 24.57M | 41.99M | 60.3M | 19.98M | 24.08M |
| Cash Only | 1.91M | 9.66M | 3.4M | 7.11M | 11.01M | 100.81M | 10.5M | 3.08M | 5.86M | 3.39M | 2.22M | 1.36M | 354K | 1.38M | 1.52M | 4M | 3.28M | 820K | 12.73M | 5.92M |
| Short-Term Investments | 133.41M | 162.14M | 86.73M | 164.74M | 183.91M | 56.46M | 124.45M | 57.7M | 54.64M | 80.36M | 43.11M | 26.9M | 6.53M | 12.72M | 20.83M | 20.57M | 38.72M | 59.48M | 7.26M | 18.16M |
| Accounts Receivable | 37.51M | 36.27M | 36.82M | 6.72M | 242.02M | 82.47M | 3.84M | 35.19M | 22.82M | 17.14M | 12.04M | 6.52M | 392K | 379K | 1.93M | 876K | 1.48M | 248K | 207K | 190K |
| Days Sales Outstanding | 1.29K | - | - | - | - | - | - | 114.87 | 278.85 | 96.53 | 105.57 | 176.08 | 265.45 | 86.46 | 117.22 | 70.68 | 256.45 | 62.69 | 64.58 | 36.06 |
| Inventory | 183K | 0 | 0 | 0 | 0 | 0 | 1.35M | 1.15M | 52.51M | 443K | 1.13M | 472K | 568K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 1.5 | - | - | - | - | - | 306.05 | 157.69 | 37.43K | 150 | 291.59 | 165.49 | 7.76 | - | - | - | - | - | - | - |
| Other Current Assets | 7.35M | 7.59M | 7.17M | 30.75M | 6.3M | 67K | 681K | 6.63M | 6.46M | 0 | 0 | 0 | 120K | 86K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 105.82M | 109.97M | 142.96M | 160.37M | 147.73M | 171.31M | 29.76M | 33.22M | 6.07M | 7.96M | 7.02M | 11.85M | 1.93M | 1.72M | 1.88M | 1.03M | 1.95M | 1.4M | 1.2M | 2.7M |
| Property, Plant & Equipment | 11.05M | 12.48M | 17.64M | 20.58M | 23.25M | 30.01M | 28.08M | 30.91M | 3.85M | 2.12M | 1.18M | 951K | 782K | 939K | 1.04M | 739K | 1.62M | 1.09M | 918K | 839K |
| Fixed Asset Turnover | 0.75x | - | - | - | - | - | - | 3.62x | 7.77x | 30.56x | 35.24x | 14.21x | 0.69x | 1.70x | 5.81x | 6.12x | 1.30x | 1.33x | 1.27x | 2.29x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60K | 164K |
| Long-Term Investments | 94.77M | 0 | 0 | 0 | 0 | 0 | 0 | 1.15M | 1.15M | 5.83M | 5.83M | 10.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 97.49M | 125.32M | 139.79M | 124.48M | 141.31M | 1.68M | 1.16M | 1.07M | 0 | 0 | 219K | 1.15M | 779K | 838K | 295K | 328K | 312K | 225K | 1.7M |
| Total Assets | 286.17M | 325.63M | 277.08M | 378.27M | 590.97M | 419.27M | 181.04M | 136.97M | 95.94M | 116.33M | 67.28M | 48.99M | 11.09M | 16.54M | 26.57M | 26.98M | 45.7M | 62.06M | 21.68M | 27.16M |
| Asset Turnover | 0.04x | - | - | - | - | - | - | 0.82x | 0.31x | 0.56x | 0.62x | 0.28x | 0.05x | 0.10x | 0.23x | 0.17x | 0.05x | 0.02x | 0.05x | 0.07x |
| Asset Growth % | -45.23% | 17.52% | -26.75% | -35.99% | 40.95% | 131.59% | 32.18% | 42.77% | -17.53% | 72.91% | 37.32% | 341.79% | -32.93% | -37.78% | -1.51% | -40.96% | -26.36% | 186.25% | -20.18% | - |
| Total Current Liabilities | 59.44M | 78.06M | 79.53M | 53.32M | 136.38M | 51.79M | 36.74M | 55.46M | 37.36M | 26.31M | 16.07M | 16.25M | 18.43M | 11.87M | 9.32M | 18.98M | 15.87M | 11.09M | 23.56M | 7.93M |
| Accounts Payable | 5.37M | 4.76M | 5.91M | 7.71M | 5.99M | 13.4M | 4.2M | 5.33M | 6.28M | 6.69M | 2.52M | 6.43M | 4.92M | 2.33M | 2.63M | 2M | 2.4M | 2.62M | 1.23M | 2.57M |
| Days Payables Outstanding | 258.25 | - | - | - | - | 3.53K | 948.41 | 732.47 | 4.48K | 2.27K | 651.16 | 2.25K | 67.12 | 46.39 | 52.05K | - | - | - | - | - |
| Short-Term Debt | 26.27M | 17.06M | 21M | 8.58M | 94.38M | 0 | 0 | 3.5M | 889K | 490K | 198K | 73K | 6.45M | 5.6M | 0 | 5.89M | 395K | 4.93M | 16.56M | 1.01M |
| Deferred Revenue (Current) | 2.82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -889K | -490K | -198K | 0 | 0 | 0 | 970K | 5.75M | 8.01M | 702K | 232K | 500K |
| Other Current Liabilities | 14.1M | 48.79M | 29.51M | 0 | 7.82M | 3.71M | 3.95M | 43.08M | 26.58M | 16.46M | 8.61M | 2.52M | 0 | 0 | 1.42M | 4.98M | 4.09M | 0 | 1.78M | 1.56M |
| Current Ratio | 3.03x | 2.76x | 1.69x | 4.09x | 3.25x | 4.79x | 4.12x | 1.87x | 2.41x | 4.12x | 3.75x | 2.29x | 0.50x | 1.25x | 2.65x | 1.37x | 2.76x | 5.47x | 0.87x | 3.08x |
| Quick Ratio | 3.03x | 2.76x | 1.69x | 4.09x | 3.25x | 4.79x | 4.08x | 1.85x | 1.00x | 4.10x | 3.68x | 2.26x | 0.47x | 1.25x | 2.65x | 1.37x | 2.76x | 5.47x | 0.87x | 3.08x |
| Cash Conversion Cycle | 1.04K | - | - | - | - | - | - | -459.92 | 33.24K | -2.02K | -254 | -1.91K | 206.09 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 290.06M | 368.8M | 380.16M | 349.94M | 368.9M | 343.7M | 265.06M | 190.53M | -41.58M | 92.83M | 88.65M | 58.98M | 35.31M | 23.05M | 231.83M | 13.55M | 9.36M | 7.83M | 89.29M | 89.17M |
| Long-Term Debt | 278.76M | 208.53M | 166.58M | 329.7M | 220.91M | 313.46M | 236.29M | 158.21M | 148.98M | 83.31M | 79.51M | 49.77M | 26.26M | 14.9M | 20.1M | 13.55M | 9.36M | 7.83M | 118K | 0 |
| Capital Lease Obligations | 32.07M | 7.25M | 13.47M | 18.14M | 22.43M | 29.13M | 28.77M | 32.32M | 1.58M | 810K | 324K | 206K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.7M | 153.02M | 200.11M | 2.09M | 125.57M | 1.11M | 0 | 0 | 8.18M | 8.72M | 8.82M | 9M | 9.05M | 8.15M | 3.69M | 0 | 0 | 0 | 89.17M | 89.17M |
| Total Liabilities | 349.51M | 446.86M | 459.69M | 403.25M | 505.29M | 395.49M | 301.79M | 245.99M | -4.22M | 119.14M | 104.72M | 75.23M | 53.74M | 34.92M | 241.15M | 32.54M | 25.23M | 18.92M | 112.85M | 97.1M |
| Total Debt | 310.63M | 239.14M | 207.02M | 361.58M | 342.02M | 347.84M | 268.84M | 194.03M | 151.45M | 84.61M | 79.71M | 49.84M | 32.71M | 20.5M | 20.1M | 19.45M | 9.76M | 12.76M | 16.67M | 1.01M |
| Net Debt | 308.73M | 229.48M | 203.62M | 354.48M | 331.01M | 247.03M | 258.34M | 190.95M | 145.59M | 81.21M | 77.49M | 48.48M | 32.35M | 19.11M | 18.58M | 15.44M | 6.48M | 11.94M | 3.95M | -4.92M |
| Debt / Equity | -4.90x | - | - | - | 3.99x | 14.63x | - | - | 0.23x | - | - | - | - | - | - | - | 0.48x | 0.30x | - | - |
| Debt / EBITDA | -2.98x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -2.96x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -17.81x | - | -6.40x | -9.93x | -7.02x | -8.74x | -6.34x | -2.73x | -7.60x | -3.85x | -7.54x | -20.02x | -20.23x | -15.82x | -21.23x | -14.15x | -18.06x | -9.43x | -73.21x | -151.92x |
| Total Equity | -63.33M | -121.23M | -182.61M | -24.98M | 85.68M | 23.78M | -120.75M | -109.02M | 650.13M | -2.81M | -37.45M | -26.23M | -42.65M | -18.38M | -214.58M | -5.55M | 20.47M | 43.15M | -91.17M | -69.94M |
| Equity Growth % | -22.59% | 33.61% | -630.93% | -129.16% | 260.32% | 119.69% | -10.76% | -116.77% | 23203.23% | 92.49% | -42.74% | 38.5% | -132.02% | 91.43% | -3763.47% | -127.13% | -52.56% | 147.33% | -30.35% | - |
| Book Value per Share | -1.00 | -1.91 | -3.14 | -0.40 | 1.37 | 0.38 | -2.11 | -2.20 | 13.38 | -0.06 | -0.93 | -0.70 | -1.28 | -0.64 | -8.88 | -0.25 | 0.96 | 5.98 | -8.48 | -4.90 |
| Total Shareholders' Equity | -63.33M | -121.23M | -182.61M | -24.98M | 85.68M | 23.78M | -120.75M | -109.02M | 650.13M | -2.81M | -37.45M | -26.23M | -42.65M | -18.38M | -214.58M | -5.55M | 20.47M | 43.15M | -91.17M | -69.94M |
| Common Stock | 720K | 716K | 580K | 611K | 628K | 626K | 616K | 542K | 490K | 482K | 438K | 380K | 342K | 304K | 259K | 224K | 219K | 213K | 57K | 56K |
| Retained Earnings | -857.63M | -913.7M | -910.35M | -753.53M | -635.72M | -683.13M | -872.67M | -734.61M | 650.13M | -523.37M | -469.89M | -403.14M | -328.05M | -254.37M | -214.58M | -176.13M | -147.59M | -118.34M | -97.25M | -73.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.25M | -3.28M | -2.73M | -2.43M | -2.23M | -2.09M | -1.79M | -2.48M | -2.08M | 41K | -99K | -4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Critical liquidity and dilution
According to reported financial statements, Omeros has maintained a persistent negative equity position over the last ten quarters, with the deficit reaching $63.3 million in 2026Q1, reflecting a structural inability to generate retained earnings sufficient to offset the ongoing accumulation of losses from clinical development activities.
The consistent negative equity suggests that the company's capital base has been entirely depleted by years of R&D spending, leaving the balance sheet reliant on external financing to remain solvent. Investors should monitor whether the recent narrowing of this deficit indicates a genuine improvement in financial health or merely a temporary accounting artifact from non-operating adjustments.
Based on Omeros's reported figures, the company carries a significant debt load of $310.6 million as of 2026Q1, which, when viewed alongside its negative equity position, suggests a highly leveraged capital structure that may limit future financing flexibility and increase the risk of further shareholder dilution.
The reliance on debt to fund operations in the absence of positive cash flow creates a precarious situation where refinancing risk becomes a primary concern. The company's debt-to-asset profile appears to be driven by necessity rather than strategic growth, which may complicate future efforts to secure non-dilutive capital.
As indicated by recent SEC filings, Omeros's cash and equivalents have dwindled to a precarious $1.9 million in 2026Q1, a level that appears insufficient to support the company's ongoing clinical trial obligations and suggests an immediate requirement for additional capital to avoid a liquidity crisis.
The current ratio of 3.03 may provide a misleading sense of security, as the underlying liquidity is heavily dependent on the timing of royalty receipts and potential asset divestitures. Given the high burn rate, the current cash position warrants extreme caution regarding the company's ability to maintain operational continuity without significant external intervention.
Data from recent financial reports suggests that Omeros's balance sheet is heavily distorted by non-cash fair value adjustments on convertible notes, which can obscure the underlying operational reality of a company that has accumulated over $850 million in negative retained earnings as of 2026Q1.
These accounting adjustments often create volatility in the reported equity and net income figures that do not correlate with the company's actual cash-on-cash performance. Analysts should look past these non-operating items to focus on the core cash burn, which remains the most accurate indicator of the company's long-term viability.
Quick answers to the most common questions about buying OMER stock.
As of 2025, Omeros Corporation (OMER) had total assets of $325.6M including $215.7M in current assets.
Omeros Corporation (OMER) carries total debt of $239.1M, offset by $171.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Omeros Corporation (OMER) has total shareholders' equity (book value) of $-121.2M ($-1.91 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Omeros Corporation (OMER) reported a current ratio of 2.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.